Resumo

ORTEGA Q, Rolando J; MOSCOTE G, Mario  e  DIAGO M, Moisés. Case Report and Literature Review: Shortened 16 Week Treatment of Patient with Genotype 2 Hepatitis C Infection. Rev Col Gastroenterol [online]. 2014, vol.29, n.3, pp.270-274. ISSN 0120-9957.

We report the case of a 46-year patient infected with genotype 2 of hepatitis C. The patient received short-course treatment with low doses of pegylated interferon alfa 2b (1 mcg/week SC k) and ribavirin (800 mg/day orally) for 16 weeks. The patient had sustained virologic response at 12 weeks (SVR12) viral and at 24 weeks (SVR24). Tolerance to treatment was very good, and there were no clinically significant signs of anemia or adverse effects. We propose that this type of therapy be considered for patients with factors associated with good prognoses such as low viral loads, low levels of fibrosis (<F2), rapid viral response (RVR) and the IL28B CC genotype. This strategy can significantly reduce the costs associated with the new direct-acting antiviral agents (DAAs) of the Sofosbuvir type associated with Ribavirin. These should be administered for 12 weeks

Palavras-chave : Hepatitis C; genotype 2; shortened dual therapy; rapid viral response.

        · resumo em Espanhol     · texto em Espanhol | Inglês     · Inglês ( pdf ) | Espanhol ( pdf )